While in Western Europe cocaine breaks records, Slovakia remains a methamphetamine kingdom. What do new data reveal about drug use?
New data highlight Slovakia's ongoing struggle with methamphetamine use, remaining a leading country in its consumption within Europe, as Western nations see rising cocaine usage.
Recent findings from the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) shed light on drug consumption trends across Europe, revealing a significant increase in cocaine use in Western Europe. Conversely, Slovakia, along with the Czech Republic, has gained notoriety as a 'methamphetamine kingdom.' Measurements taken from wastewater treatment facilities indicate that both Bratislava and Prague are leading Europe regarding methamphetamine consumption, with usage levels exceeding the European median by substantial margins. The low cost and widespread availability of methamphetamine in Slovakia are major factors contributing to its prevalent use.
Sociologist Robert Klobucký points to the ease of manufacturing methamphetamine in local neighborhoods and the availability of precursors as reasons for the drug's persistence and popularity. Despite the alarming rise in cocaine consumption in other parts of Europe, such as Spain and the Netherlands, Slovakia's drug scene continues to be dominated by methamphetamine, reflecting differing regional drug markets and social factors. Klobucký emphasizes that the socio-economic conditions in Slovakia may create an environment where methamphetamine remains a preferred choice for many users due to its accessibility and low cost.
The implications of these trends raise concerns for public health and policy in Slovakia, where the government and health officials need to address not only prevention and treatment options for methamphetamine use but also the emerging challenges posed by the rising cocaine trends seen in neighboring countries. The stark contrast between the uptick in cocaine usage in Western Europe and the entrenched presence of methamphetamine in Slovakia signals a need for targeted interventions tailored to the specific complexities of the Slovak drug landscape.